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drugs, including a diuretic). A subset of patients (n129) is being followed to 3 years
post-RDN (35 consented to laboratory assessments to 3 years). The primary endpoint is
change in office-based BP from baseline. Data collection includes office-based BP
measurement every 6 months, renal function, electrolytes, and medication usage.
Results: A total of 34 patients have reached the 3 year follow-up time point (9 with labs).
Baseline BP was 175/9812/11 mmHg. Mean SBP change post-RDN was -18.016.6
mm Hg at 1 month, -28.4 17.6 mm Hg at 6 months, -27.6 16.3 mm Hg at 2 years
and -31.3 14.9 mm Hg at 3 years. Medication usage remained similar to baseline with
35% aldosterone antagonist, 85% beta blocker and 82% calcium channel blocker use at
baseline and at 3 years; diuretic use 91% and 88%, angiotensin receptor antagonists 71% and
76%, and ACE inhibitors 50% and 59% at baseline and 3 years, respectively. At 3 years
estimated glomerular filtration rates (eGFR) declined by -13.212.1 from a baseline of
82.216.1 mL/min/m2.
Conclusions: Among patients with full 3 year follow-up, RDN results in significant,
sustained lowering of SBP in patients with treatment-resistant hypertension and a baseline
SBP 160 mm Hg. Antihypertensive medication usage was similar at baseline and 3 years.
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Aims: To evaluate the clinical safety and effectiveness of the DESolve™ Myolimus-
Eluting Bioresorbable Coronary Scaffold (BCSS)in patients with single de novo native
coronary artery lesions through clinical endpoints and multiple imaging modalities.
Methods and Results: Background: The DESolve BCSS is a novel drug eluting device
that combines a PLLA-based scaffold coated with a bioresorbable polylactide-based
polymer and the drug Myolimus. Myolimus, a macrocyclic lactone mTOR inhibitor has
demonstrated potent anti-proliferative properties in two First-in-Man (FIM) trials using
Elixir’s metallic Myolimus-eluting coronary stents. Drug dose is 3 mcg per mm of scaffold
length; the same dose used in the FIM studies. Sixteen patients with single, de novo
coronary artery lesions were enrolled in this prospective, multi-center, single-arm FIM
study. One patient did not receive a study stent and was deregistered. The 15 remaining
patients are being analysed for multiple clinical endpoints: Device and Procedure Success;
Major Adverse Cardiac Events (MACE), a composite endpoint of cardiac death, target
vessel MI, and clinically-indicated target lesion revascularization (CI-TLR); clinically-
indicated Target Lesion and Target Vessel Revascularization, (CI-TVR) and stent
thrombosis assessed at 1, 6 and 12 months and annually to 5 years. Multiple assessments
by angiographic, IVUS and OCT at 6 months were completed. An additional analysis
using multislice computed tomography (MSCT) will be completed at 12 and 24 months.
At 6 months, the in-scaffold late lumen loss was 0.19  0.19 by QCA, the % volume
obstruction was 7.18  3.37 by IVUS, and by OCT 98.68  2.44% of struts were
demonstrated as covered. There was one MACE event, a TLR, during the follow-up
period. Detailed clinical and imaging results through 12 months will be presented.
Conclusion: The DESolve™ Myolimus-Eluting BCSS demonstrated both excellent
safety and effectiveness in this FIM study, thus warranting further clinical evaluation of the
novel technology in larger clinical studies. Detailed clinical and imaging results through 12
months will be presented.
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Background: The reasons for switching from prasugrel back to clopidogrel after
percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) are
unclear, but are frequently practiced. The study aims to compare the characteristics and
in-hospital outcomes of patients initially given prasugrel but was switched back to
clopidogrel versus those who were continued on prasugrel on discharge.
Methods: The study included a cohort of 152 consecutive AMI patients who were first
loaded with prasugrel and underwent PCI. Patients were categorized into switched
therapy to clopidogrel on discharge (Switched, n58) and continued therapy on prasugrel
on discharge (Continued, n94). Patient and procedural characteristics, as well as
PCI-related complications and in-hospital outcomes were evaluated.
Results: Baseline demographics and procedural characteristics of both groups were
similar. Patients who switched to clopidogrel on discharge had significantly longer
hospital stay, and intensive care unit stay trended longer. Switched patients had
significantly higher incidence of blood transfusions. Major bleeding, hematocrit drop,
hematoma and urgent coronary artery bypass grafting (CABG) also trended higher in
patients who switched therapy.
Concomitant coumadin therapy was significantly higher in the switched therapy group,
whereas aspirin therapy was similar in both groups. No in-hospital mortality or myocardial
infarction occurred in either groups (Table).
Conclusion: In-hospital bleeding complications requiring blood transfusion, need for
urgent CABG and concomitant coumadin therapy are the main reasons for switching of
antiplatelet therapy from prasugrel to clopidogrel prior to discharge.







Length of stay in intensive
care unit (days)
1.1 1.5 0.7 1.0 0.051
Overall hospital length of
stay (days)
4.3 4.3 2.9 1.8 0.021





3 (5.2%) 0 0.054
Blood transfusion 7 (12.1%) 0 0.001
Major bleeding 4 (6.9%) 1 (1.1%) 0.070
Hematocrit drop 15% 5 (8.5%) 1 (1.1%) 0.060
Hematoma 4 (6.9%) 1 (1.1%) 0.070
Concomitant coumadin
therapy on discharge
10 (17.2%) 5 (5.3%) 0.017
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Background: Thrombin injection has been the treatment of choice for iatrogenic arterial
pseudoaneurysms (PSAs). However, certain morphological features of the PSA, i.e. neck
width and length, occasionally precludes the use of this treatment option using the current
recommended technique.
Methods: Between March 2008 and June 2012, 146 consecutive patients who underwent
thrombin injection for post percutaneous coronary intervention related PSAs were
retrospectively studied. The technique of injecting as superficial and as far from the PSA
tract is compared with injecting at the ‘neck’ of the PSA.
Results (Table) Ninety-one patients had superficial thrombin injection (STI) and 55
patients had neck thrombin injection (NTI). Baseline characteristics were similar in both
groups. At the time of injection, all patients were on dual antiplatelet therapy and 9.6%
were on oral anti-coagulation therapy without significant difference between both groups.








Patients in the NTI cohort tended to have ‘shorter’ neck. The NTI technique utilized
lesser amount of Thrombin with a trend to a higher success rate and lesser recurrence. The
two patients in the NTI group with recurrent PSA on follow-up imaging study were both
on Coumadin and both PSAs were successfully treated with re-injection of Thrombin. No
serious complications were observed including thromboembolism, limbischemia, aneu-
rysm rupture, or abscess formation.
Conclusion: Femoral pseudoaneurysm closure using the NTI technique is a safe and
efficacious treatment modality. This offers a non-surgical treatment option for PSAs with




(n  91) P value
Amount of thrombin[IU]
Mean (SD) 994.55 (920) 1501.52 (1384.7) 0.02
Neck length [mm]:
Min; max 0; 2.43 0.13; 3.3
Mean (SD) 0.76 (0.56) 1.06 (0.66) NS
Neck width [mm]:
Min; max 0.1; 2.0 0.1; 2.3
Mean (SD) 0.67 (0.47) 0.78 (0.47) NS
Number of sacs:
1 37 (66.1%) 57 (62.6%)
2 15 (26.8%) 28 (30.8%)
3 4 (7.1%) 6 (6.6%) NS
Success 56 (100%) 87 (96.7%) NS
Recurrence 2 (3.8%) 11 (12.6%) NS
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Background: In the Valentines II trial, the use of second-generation DIOR® paclitaxel
drug-coated balloon (DCB) as adjunct therapy to plain old balloon angioplasty (POBA)
has shown good clinical outcomes in patients with de novo coronary lesions with low rates
of major adverse cardiac events (MACE). We report the quantitative coronary angiog-
raphy (QCA) results of the subset of patients who underwent angiographic follow-up.
Methods: Valentines II trial prospectively enrolled 103 patients with de novo lesions of
50% stenosis who presented with angina and/or documented ischemia on stress testing.
Patients underwent POBA followed by DCB, and in cases of suboptimal angiographic
success additional bail-out stenting was performed. Primary endpoint was MACE at 6-9
months. A subset of patients underwent angiographic follow-up with QCA.
Results: For the study population, MACE, target vessel revascularization and target
lesion revascularization rates were 8.7%, 6.9% and 2.9% respectively. Angiogram was
performed in 35 patients (34%) at mean follow-up of 227  40 days. The QCA results
are shown (Table). Late-luminal loss at follow-up was 0.38  0.39 mm and binary
restenosis was 14.3%.
Conclusion: The result of the Valentines II trial angiographic cohort demonstrates the
efficacy of second generation DIOR® DCB as adjunct to POBA in treating patients with
de novo coronary lesions. This approach achieved low late-luminal loss and binary
restenosis at intermediate-term angiographic follow-up and should be considered for
patients and lesions not suitable for drug-eluting stents.
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Background: The Resolute Integrity zotarolimus-eluting stent utilizes novel continuous
sinusoid technology (CST). With CST, a single cobalt alloy wire is formed into a
repeating sinusoidal pattern, wrapped helically and fused to improve conformability,
provide greater flexibility and ease of delivery without compromising other important stent
design characteristics like radial and longitudinal strength. The objective of the
DELIVER study was to evaluate delivery success as well as in-hospital outcome following
use of the Resolute Integrity stent in an all-comers large patient population.
Methods: DELIVER is a prospective, multicentre, single arm, open-label, observational
study in 163 centers in 33 countries. Patients with coronary artery disease and a lesion of
reference vessel diameter of 2.25 to 4.0 mm were eligible for inclusion. Group 1 received
the Resolute Integrity stent as the first choice of stent treatment and Group 2 were treated
following delivery failure of another stent type. The primary endpoint for the study was
delivery success defined as complete passage of the stent across the target lesion with full
expansion to the desired diameter at the desired location. Other endpoints are in-hospital
clinical outcomes adjudicated by a clinical event committee.
Results: A total of 7740 patients (12165 stents in 10449 lesions) were enrolled between
February 2011 and June 2012. Patients suffered from diabetes mellitus in 34.9% and acute
myocardial infarction 28.4%. Procedure approach was radial in 46.0%, brachial in 0.6% or
femoral in 53.3%. Multiple lesions were treated in 26.9%, pre-dilatation performed in
67.4% and post-dilation in 39.3%. Lesions were de-novo in 94.5% and restenotic in 5.5%.
Type B2/C lesions were treated in 58.8%. Reference diameter pre stent implantation was
2.930.48mm. The primary endpoint delivery success was high with 98.9% [95% CI
98.7-99.1%] in group I and 98.0% [95% CI 89.1-99.9%] in group 2. Adjudicated
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